Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Sies, Helmut / Thomas, Douglas D. / Turk, Boris / Wittinghofer, Alfred

12 Issues per year


IMPACT FACTOR 2016: 3.273

CiteScore 2016: 3.01

SCImago Journal Rank (SJR) 2016: 1.679
Source Normalized Impact per Paper (SNIP) 2016: 0.800

Online
ISSN
1437-4315
See all formats and pricing
More options …
Volume 392, Issue 12 (Dec 2011)

Issues

Squalene monooxygenase – a target for hypercholesterolemic therapy

Agnieszka Belter
  • Institute of Bioorganic Chemistry, Polish Academy of Science, Noskowskiego 12/14, 61-704 Poznan, Poland
  • AdvaChemLab, Topazowa 8, 61-680 Poznan, Poland
  • BioInfoBank Institute, Limanowskiego 24A, 60-744 Poznan, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Miroslawa Skupinska
  • Institute of Bioorganic Chemistry, Polish Academy of Science, Noskowskiego 12/14, 61-704 Poznan, Poland
  • BioInfoBank Institute, Limanowskiego 24A, 60-744 Poznan, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Malgorzata Giel-Pietraszuk
  • Institute of Bioorganic Chemistry, Polish Academy of Science, Noskowskiego 12/14, 61-704 Poznan, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Tomasz Grabarkiewicz / Leszek Rychlewski / Jan Barciszewski

Abstract

Squalene monooxygenase catalyzes the epoxidation of C-C double bond of squalene to yield 2,3-oxidosqualene, the key step of sterol biosynthesis pathways in eukaryotes. Sterols are essential compounds of these organisms and squalene epoxidation is an important regulatory point in their synthesis. Squalene monooxygenase downregulation in vertebrates and fungi decreases synthesis of cholesterol and ergosterol, respectively, which makes squalene monooxygenase a potent and attractive target of hypercholesterolemia and antifungal therapies. Currently some fungal squalene monooxygenase inhibitors (terbinafine, naftifine, butenafine) are in clinical use, whereas mammalian enzymes’ inhibitors are still under investigation. Research on new squalene monooxygenase inhibitors is important due to the prevalence of hypercholesterolemia and the lack of both sufficient and safe remedies. In this paper we (i) review data on activity and the structure of squalene monooxygenase, (ii) present its inhibitors, (iii) compare current strategies of lowering cholesterol level in blood with some of the most promising strategies, (iv) underline advantages of squalene monooxygenase as a target for hypercholesterolemia therapy, and (v) discuss safety concerns about hypercholesterolemia therapy based on inhibition of cellular cholesterol biosynthesis and potential usage of squalene monooxygenase inhibitors in clinical practice. After many years of use of statins there is some clinical evidence for their adverse effects and only partial effectiveness. Currently they are drugs of choice but are used with many restrictions, especially in case of children, elderly patients and women of childbearing potential. Certainly, for the next few years, statins will continue to be a suitable tool for cost-effective cardiovascular prevention; however research on new hypolipidemic drugs is highly desirable. We suggest that squalene monooxygenase inhibitors could become the hypocholesterolemic agents of the future.

Keywords: cholesterol; drug design; epoxidation; hypercholesterolemia

About the article

Corresponding author


Received: 2011-08-10

Accepted: 2011-10-08

Published in Print: 2011-12-01


Citation Information: Biological Chemistry, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/BC.2011.195.

Export Citation

©2011 by Walter de Gruyter Berlin Boston. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Janusz M. Bujnicki, Jerzy Tiuryn, and Teresa M. Przytycka
PLoS Computational Biology, 2013, Volume 9, Number 5, Page e1003048
[2]
Nuno M. F. S. A. Cerqueira, Eduardo F. Oliveira, Diana S. Gesto, Diogo Santos-Martins, Cátia Moreira, Hari N. Moorthy, Maria J. Ramos, and P. A. Fernandes
Biochemistry, 2016, Volume 55, Number 39, Page 5483
[3]
Feifei Chen, Hongxia Di, Youxin Wang, Qiao Cao, Bin Xu, Xue Zhang, Nana Yang, Guijie Liu, Cai-Guang Yang, Yong Xu, Hualiang Jiang, Fulin Lian, Naixia Zhang, Jian Li, and Lefu Lan
Nature Chemical Biology, 2016, Volume 12, Number 3, Page 174
[4]
David N. Brown, Irene Caffa, Gabriella Cirmena, Daniela Piras, Anna Garuti, Maurizio Gallo, Saverio Alberti, Alessio Nencioni, Alberto Ballestrero, and Gabriele Zoppoli
Scientific Reports, 2016, Volume 6, Number 1
[5]
Federica Maione, Simonetta Oliaro-Bosso, Claudia Meda, Federica Di Nicolantonio, Federico Bussolino, Gianni Balliano, Franca Viola, and Enrico Giraudo
Scientific Reports, 2015, Volume 5, Number 1
[6]
Xiyan Mu, Kai Wang, Tingting Chai, Lizhen Zhu, Yang Yang, Jie Zhang, Sen Pang, Chengju Wang, and Xuefeng Li
Environmental Pollution, 2015, Volume 197, Page 278
[7]
Wei Jiang and Bao-Liang Song
Diabetes & Metabolism Journal, 2014, Volume 38, Number 3, Page 171
[8]
Bijan Zare, Zargham Sepehrizadeh, Mohammad Ali Faramarzi, Mohammad Soltany-Rezaee-Rad, Sassan Rezaie, and Ahmad Reza Shahverdi
Biotechnology and Applied Biochemistry, 2014, Volume 61, Number 4, Page 395
[10]
Wolf-Dieter Lienhart, Venugopal Gudipati, and Peter Macheroux
Archives of Biochemistry and Biophysics, 2013, Volume 535, Number 2, Page 150
[11]
Valéria Maria Caselato-Sousa and Jaime Amaya-Farfán
Journal of Food Science, 2012, Volume 77, Number 4, Page R93

Comments (0)

Please log in or register to comment.
Log in